The most complete archive of clinical and pathology lab industry news available, including issues from 1997 to the present.
CLINICAL LABORATORY MANAGERS will learn in this issue about two trends that are driving a movement to standardize laboratory operations across large regions: the integration of clinical care and the need for hospitals and health networks to improve patient outcomes continuously. THE DARK REPORT dives deeply into the details of an ambitious program along these lines in Michigan. Also, Theranos’ dying breath is detailed as the once-vaunted company finally goes under.
THE DARK REPORT HAS UNCOVERED a previously unnoticed trend that turns common wisdom on Wall Street upside down: Hospitals and health systems may be taking back control of their their laboratory outreach programs instead of selling them, and committing major resources to their inpatient labs instead of outsourcing their management. TDR is the first to analyze this trend in three separate articles. Also, for both anatomical and clinical pathology, value-based payment is coming, creating an opening for pathologists who move quickly.
THE DARK REPORT DEMONSTRATES that CMS is once again seemingly ignoring Congress’ intent with the Protecting Access to Medicare Act (PAMA) by leaving out hospital labs and outreach laboratories from price reporting. What will the outcome be this time around? Also, only TDR has detected a potential opportunity in managed care contracting for regional and outreach labs that can demonstrate how they add value to patient care.
A CRISIS IN IRELAND has put two American laboratories in the crosshairs of potentially disastrous news reports, which, as THE DARK REPORT demonstrates, can quickly undermine the credibility – and profitability – of any lab. Also, THE DARK REPORT is first in the industry to call attention to new developments in the lab testing marketplace that have the potential to influence all clinical labs and pathology groups – in this case, the decision by two innovative health networks to make genetic tests available to their patients at primary care clinics.
THE DARK REPORT sums up a tale of two fraudsters: Two counts of conspiracy, nine counts of wire fraud, the possibility of a lifetime in prison and $2.75M in fines each for Theranos’ Elizabeth Holmes and Ramesh “Sunny” Balwani. What does it all mean for tech startups – and clinical labs? Also, this issue delivers specific strategies that lab outreach directors can use to overcome current challenges and protect revenue, increase market share, and contribute to better patient care.
THE DARK REPORT HAS DISCOVERED an intriguing but quiet trend in recent months: Lab companies are suddenly snatching up struggling rural hospitals to take advantage of their higher payment rates in what is called “pass-through billing,” a process that can and has strayed over the line into illegal territory. Interestingly, the businessman involved in one such recent transaction insists he “ran away as fast as possible” from an earlier company that was engaged in some sketchy billing schemes. Also in this issue, John Carreyrou of The Wall Street Journal describes his shocking experiences as he dug into, and later exposed, the now-infamous Theranos pyramid scheme.
THE FUTURE OF THE LAB INDUSTRY was outlined in detail at the most recent Executive War College: Despite the challenges ahead, there are also tantalizing opportunities – but enterprising labs must pursue them vigorously. This intriguing finding is supported by a Cleveland Clinic test utilization management project also reported in this issue. In an exclusive analysis, THE DARK REPORT shows how the lab’s seven-year effort has prevented 160,072 tests and saved more than $5 million, while also improving quality and patient safety, and enhancing patient care and experience.
THE DARK REPORT digs into the shocking path lab deficiencies found at Wake Forest Baptist Medical Center and discovers that labs with a single individual with critical compliance, training and oversight responsibilities could leave them in the same dangerous position. Also, analysis in this issue helps lab executives understand the issues in the PAMA lawsuit against HHS to better prepare them to educate their elected officials.
HERE’S A FIRST LOOK at an important new trend: At first, it probably will have the greatest impact on anatomic pathology groups that perform cancer tests. But even clinical labs will find themselves dealing with new factors in the lab testing marketplace—particularly the ability to access or license valuable assays that incorporate the latest diagnostic technologies. Also in this issue are the latest developments in the tale of a lab company that made an early splash in drugs-of-abuse and pain management testing almost two decades ago, but is now going out of business, in part due to lingering allegations of abusive sales and billing practices.
THE DARK REPORT WAS THE FIRST to draw attention to the increasingly popular “HOPD” billing scheme last November. Now it digs deeply into the details of new case that offers confirmation that insurers are resisting such schemes, as Anthem is poised to sue a tiny California hospital if it does not recover $13.5 million in a timely fashion. Also, TDR gives an exclusive analysis of documents in the PAMA lawsuit filed against CMS — including the revelation that CMS appears to have deliberately calculated how much Medicare could save by ignoring certain data, instead of basing the new fees on all the data requested by Congress.
Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.
